Background :Leiomyoma of the uterus is a benign tumour essentially composed of smoothmuscle tissue and variable amount of fibrous connective tissue. Itis themost commontum our of the uterus and is found in 20 % of women in the reproductive age group.Thesymptoms include menstrual disturbances, commonly menorrhagia and dysmenorrhea. Mifepristone on the other hand is a progesterone receptor modulator with mainly antagonisticproperties. Objectives: To study the effect of Mifepristone daily for 3 months on improvement of fibroidrelated symptoms and on the size of uterine fibroid and evaluate its role as a surgical sub stitute in patients who have fibroid associated anaemia, small to medium fibroids, women who want to preserve uterus and in cases where fibroids are unresectable or surgery is difficult. Materials and methods: It was an institutional based prospective study. It was conducted in Eden Building, Department of Gynaecology and Obstetrics in Medical College and Hospital, Kolkata, West Bengal,India.After receiving the clearance from the ethical committee study was conducted within 18 months period (March 2021 to September 2022).105 patients were included in this study.The data were entered in MS Excel spreadsheet and analysis was done using Statistical Package for Social Sciences (SPSS) version 21.0. Result: The mean age of the study population was 33.19 years .Menorrhagia was the predominantsymptom among 48.6%. Majority of the subjects had intramural fibroid(37.1%).The meanPBAC score and Numeric pain rating scale score decreased significantly at the end of 3monthstherapy. Theme anuterine volume, fibroid volume decreased and endometrial thickness and mean Hb level increased significantly at the end of3monthstreatment. Conclusion: It can be concluded that at the end of 3 months, there was significant reductionin fibroid related symptoms, uterine and fibroid volume and improvement in haemoglobin level.